Scientific Program

İstanbul MS Days

 

16:00-17:00 Panel I
Rational use and cost effectiveness of diagnostic tools in MS and related disorders in Turkiye (In Turkish)
Chairs: Kadriye Ağan
Panelists: Serpil Bulut, Levent Sinan Bir, Serpil Demirci, Haluk Gümüş, Mesrure Köseoğlu, Bilgin Öztürk
17:00-17:45 Satellite Symposium – Sanovel
Experience of Teriflunomide with Cases
Chairs: Ayşe Nur Yüceyar, Murat Terzi
1. Treatment Experiences and Decision-making
2. ⁠The Importance of Current Biomarkers in Treatment Strategies
Speakers: Nilüfer Kale İçen, Mehmet Fatih Yetkin
17:45-18:00 Break
18:00-19:30 Panel II
Treatment options and barriers in treating the individual with MS in Turkiye (In Turkish)
Chairs: Ömer Faruk Turan, Sabahattin Saip
Panelists: Sıla Usar İncirli, Ufuk Aluçlu, Münife Neyal, Cavit Boz, Sema Saltık, Esra Gürsoy
19:30-19:45 Rational Drug Use
Session Chair: Saltanat Mert
Speaker: Tahir Yoldaş
  Dinner
08:00 - 09:00 Oral Poster Presentations
  Poster Station I
Dürdane Aksoy, Yaşar Altun
  Poster Station II
Ferah Kızılay, Gürdal Orhan
  Poster Station III
Nuray Bilge, Abdülkadir Tunç
  Poster Station IV
Emine Rabia Koç, Ahmet Kasım Kılıç
  Poster Station V
İrem Tiftikçioğlu, Yusuf Tamam
09:00 – 09:45 Morning Satellite - Abdi İbrahim
SIGNIFICANT ADVANCEMENTS IN MS TREATMENT: Fampiridine in Symptomatic Management
Chair: Murat Terzi
  The Fampiridine Molecule in Multiple Sclerosis: Key Clinical Studies
Application of Fampiridine in Clinical Practice
Fampiridine Therapy: Case Study Insights
Speaker: Melih Tütüncü
10:00 - 10:45 Effective Presentation Skills for Scientists
Janet Hafler
Chairs: Nilüfer Kale İçen, Nefati Kıylıoğlu
11:00 – 12:00 TURKISH MS PANEL - In Turkish
Building future-proof careers for young MS specialists in Türkiye
Chairs: Murat Terzi, Mehmet Fatih Yetkin
Speakers: Serkan Demir, Atay Vural, Tuncay Gündüz, Sedat Şen
12:00-12:45 Lunch & Satellite Symposium - Merck
Mavenclad Usage in MS Treatment
Chair: Cavit Boz
  Mavenclad in MS Treatment
Serhan Sevim
  Mavenclad Usage in Elderly Patients
Bruce Hughes
13:00 – 14:00 OFFICIAL OPENING
13:00 – 13:10 Welcome address 1: History of Istanbul MS Days
Aksel Siva
13:10 – 13:20 Welcome address 2: From local roots to global aspirations – Dark Side of the Moon?
Orhun H. Kantarci
13:20 – 17:20 SESSION-1 / I: From Posers’ Criteria to refined disease definitions of 2024 in inflammatory demyelinating diseases
Discussants & Chairs: Jack Antel & Husnu Efendi & Axel Petzold
13:20 – 13:40 The clinician-scientist – finding the right questions for the right answers
Brian G. Weinshenker
13:40 – 14:00 The scientist-clinician – using epidemiology evidence to develop individualized clinical practice
Ellen Mowry
14:00 – 14:20 The clinician-clinician – Value of experience-based medicine in the extremes of disease
Thomas Berger
14:20 – 14:40 The scientist-scientist – Developing models that reflect clinical questions accurately
Katerina Akassoglou
14:40 – 15:00 Discussion
15:00 – 15:20 Break
15:20 – 17:00 SESSION-1 / II: Updates in Diagnostic Criteria and phenotyping definitions of inflammatory demyelinating diseases in 2024 and beyond
Discussants & Chairs: Jack Antel & Husnu Efendi & Axel Petzold
15:20 – 15:40 The 2024 MS Diagnostic Criteria – What does it change?
Xavier Montalban
15:40 – 16:00 Upcoming IPND-2025 Criteria – Will it add anything?
Kazuo Fujihara
16:00 – 16:20 Real world use examples of CVS & PRLs
Jiwon Oh
16:20 – 17:00 Do we need more detailed or more practical diagnostic criteria?
Chairs
17:00 – 17:30 Q&A, Discussion
17:30 – 17:50 Break
17:50 – 20:00 SESSION-2: Can we use science to fine tune health care delivery to the underserved?
Discussants & Chairs: Aslı Tuncer & Mohamadali Sahraian & Magd Zakaria
17:50 – 18:10 The real-world needs of the underserved countries
Riad Goudhier
18:10 – 18:30 Pitfalls in quantifying needs of the underserved and how to improve it
Rana Karabudak
18:30 – 18:50 Socialized vs. free-market economy for delivering healthcare to people in need
Andrew Chan
18:50 – 19:20 Objective definitions of race & ethnicity – beyond the conventional
Philip L. De Jager
19:20 – 19:50 Q&A, Discussion
20:00 Dinner
08:00 - 09:00 Oral Abstract Presentations
  HALL A
Ayşe Sağduyu Kocaman, Aylin Akçalı
  HALL B
Özlem Ethemoğlu, Aslı Köşkderelioğlu
  HALL C
Erdem Toğrol, Belgin Petek Balcı
  HALL D
Semra Öztürk Mungan, Caner Feyzi Demir
  HALL E
Yılmaz İnanç, Mehmet Tecellioğlu
09:00 – 09:15 Break
09:15 – 09:35 Adjusting for geography in epidemiology studies in MS
Alberto Ascherio
09:35 - 09:40 Q&A, Discussion
09:40 – 12:00 SESSION-3: Translating existing biomarkers to clinic?
Discussants & Chairs: Naila Makhani &Yesim Beckmann & Erdem Tüzün
09:40 - 10:00 Low field portable MRI - effective deployment to clinic –
Serhat Okar
10:00 -10:20 Utility of cervical cord MRI in MS diagnosis and prognosis
Cristina Azevedo
10:20 – 10:40 Break
10:40 – 11:00 CSF biomarkers in MS
Hayrettin Tumani
11:00 – 11:20 Integrating multiple biomarkers to diagnose, prognosticate and treat in the real world – The RIS experience
Darin Okuda
11:20 – 12:00 Q&A, Discussion
12:00 – 12:45 Lunch Satellite Symposium (Farmanova/ Novartis)
Chair: Hüsnü Efendi
A New Era of B Cell Therapies: Ofatumumab
Speaker: Patrick Vermersch
13:00 – 15:20 SESSION-4: Translating “futureomics” to clinic today?
Chairs / Panelists: Eda Tahir Turanlı & Boris Zalc
13:00 – 13:20 Role of genomics in early diagnosis of MS
Anat Achiron
13:20 - 13:40 Power of bioinformatics to solve complex proteomics of MS -
Mika Gustafsson
13:40 – 14:00 Immunomics to practice in MS
Amit Bar-Or
14:00 – 14:20 Break
14:20 – 14:40 Radiomics to delineate complex phenotypes in MS
Korhan Büyüktürkoğlu
14:40 - 15:00 Pitfalls of integrating omics – human vs AI?
Vilas Menon
15:00 – 15:20 Q & A Discussion
15:20 - 15:40 Break
15:40 – 18:00 SESSION-5: The MS continuum - polymorphic definition of relapses and progressive MS
Discussants & Chairs: Nur Yuceyar & Refik Pul & Ugur Uygunoglu
15:40 – 16:00 The pathologist’s view of MS phenotypes
Bruce Trapp
16:00 – 16:20 MRI markers of MS phenotypes
Daniel Ontaneda
16:20 - 16:40 Non-MRI imaging biomarkers of MS phenotypes
Peter A. Calabresi
16:40 – 17:00 Break
17:00 – 17:20 Relapses & Pseudorelapses – do we need updated definitions
Eoin P. Flanagan
17:20 - 17:40 Towards practical composite metrics of preclinical and subclinical MS definitions
Orhun Kantarcı
17:40 – 18:00 Q&A, Discussion
18:00 - 18:20 Break
18:20 – 19:50 SESSION-6: Using molecular imaging in MS – towards a practical goal
Discussants & Chairs: Catherine Lubetzki & Murat Kürtüncü
18:20 - 18:40 PET markers of myelin and oligodendrocytes
Burcu Zeydan
18:40 – 19:00 PET markers of microglia function
Laura Airas
19:00 – 19:20 PET Astrocyte imaging markers
Bruno Stankoff
19:20 - 19:50 Q&A, Discussion
20:15 Dinner
08:15 - 09:00 Morning Satellite - Alexion
Exploring AQP4+ NMOSD: Diagnosis, Pathophysiology and Eculizumab Treatment through Case Studies
08:15-08:35 Opening, AQP4+ NMOSD Pathophysiology and Diagnosis of the Disease
Ayşe Altıntaş
08:35-08:55 Eculizumab Treatment in Patients Diagnosed with AQP4+ NMOSD, Case Examples
Kazuo Fujihara
08:55-09:00 Q&A
09:00 – 09:15 Break
09:15 – 12:00 SESSION-7: The treatment of MS today and tomorrow
Chairs / Panelists: Ayşe Altıntaş & Dimitrios Karussis
09:15 - 09:35 Treating MS in the young age
Silvia Tenembaum
09:35 – 09:55 How to treat MS in the old age
Nikolaos Grigoriadis
09:55 - 10:15 Hormones and adjunct therapies in MS
Kerstin Hellwig
10:15 - 10:30 Break
10:30 – 10:50 New developments in B cell depletion
David Hafler
10:50 – 11:10 Microglia targets – BTK inhibitors and beyond  
Daniel Reich
11:10– 11:30 How to apply advanced imaging modalities for future clinical trials
Nicola De Stefano
11:30 – 12:00 Q&A, Discussion
12:00 – 12:45 Lunch & Satellite Symposium - Roche
Chair: Uğur Uygunoğlu
Timing of Ocrelizumab in MS: Clinical impact and efficacy of On Time Initiation
Enric Monreal Laguillo
13:00 – 15:30 SESSION-8: Rethinking trial design in multiple sclerosis
Chairs / Panelists: Hans-Peter Hartung & Melih Tutuncu & Ugur Bilge
13:00 – 13:20 Sex and ethnicity impact on clinical trial results
Nabeela Nathoo
13:20 - 13:40 Impact of limited recovery from relapses in practice and in clinical trials
Claire Riley
13:40 – 14:00 Designing future proof clinical trials with multiple variables a priori
Maria Pia Sormani
14:00 – 14:20 Break
14:20 – 14:40 Missing spinal cord data and beyond in clinical trials – mismatch with clinical practice
Matilde Inglese
14:40 - 15:00 Using AI to model for prognostic variables in clinical trials
Cristina Granziera
15:00 – 15:30 Q & A, Discussion
15:30 - 15:45 Break
15:45 – 18:30 SESSION-9: Treating the whole spectrum
Discusssants & Chairs: Nasrin Asgari & Paulus Rommer & Najib Kissani
15:45 – 16:05 Sensitivity and specificity of laboratory biomarkers in MS, NMO and MOG
Orhan Aktas
16:05 – 16:25 The challenges of treating overlapping autoimmune diseases with MS
Aksel Siva
16:25 – 16:45 The new NMO era of treating NMO – What should be the first line?
Friedemann Paul
16:45 – 17:05 Treating MOGAD – where are we now?
Jacqueline Palace
17:05- 17:30 Discussion
17:30 – 17:45 Break
17:45- 18:45 SESSION-10: Innovations in MS
Chairs: Gülşen Akman Demir & Serhan Sevim
17:45 – 18:05 Where is the next innovation in treating inflammatory-demyelinating disease spectrum
Heinz Wiendl
18:05 – 18:25 mRNA vaccines for MS and autoimmune diseases
Mustafa Diken
18:25 – 18:45 Q&A, Discussion
18:45 – 19.15 Istanbul MS Days Lecture
Chairs: Rana Karabudak & Husnu Efendi & Orhun Kantarcı & Aksel Siva
  Patient reported outcomes in MS - What will be the role of PROs in future MS care?
Giancarlo Comi
19:15 – 20:15 Summary and review of the meeting by the young Turkish MS Experts
Chairs: Özgül Ekmekçi, Burcu Altunrende
Panelists: Cihat Uzunköprü, Bilge Piri Çınar, Meral Seferoğlu, Mesude Tütüncü, Destan Bünül
20:30 Faculty - Farewell Dinner